Bayer Stake In OTC Pravachol Could Influence Bristol OTC Unit Divestiture
This article was originally published in The Tan Sheet
Executive Summary
Bayer could have a financial interest in Bristol-Myers Squibb's consumer franchise due to its Pravachol OTC marketing agreement regardless of whether it purchases the unit